ARTHEx Biotech is a Valencian clinical-stage biotechnology company focused on developing targeted RNA therapeutics for rare genetic neuromuscular disorders. Its lead program, ATX-01, is currently in c...
La ronda de financiación en la que participan CDTI Innovación y NARA Health Capital, junto con Invivo Ventures, permitirá a Gyala llevar a cabo un ensayo clínico de Fase I en pacientes con leucemi...
Researchers at Pulmobiotics, a start-up founded in 2020 at the Centre for Genomic Regulation (CRG) in Barcelona backed by Invivo Ventures, have begun work on a ‘living medicine’ to improve the eff...
El CDTI, a través de su programa Innvierte, conjuntamente con Invivo Ventures, han alcanzado un acuerdo con los socios de Telomere Therapeutics, S.L. para entrar en el capital de la startup. La aport...
Telum Therapeutics (‘Telum’), an emerging biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages, called enzybiotics, has ...
El CDTI, a través de su programa Innvierte, conjuntamente con Invivo Ventures, han alcanzado un acuerdo con los socios de Arthex Biotech, S.L. para entrar en el capital de la startup. La aportación ...
Hospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating hematological malignancies. The company raised
Stopping now would be a mistake, because science and biotechnology will play a huge role in society and, for those who don’t stop now, having the advantage of these 2 quarters will be key. It is tim...